____________________________________________________________________________________________________________ Exelixis
with CRC. The agency set a Prescription Drug User Fee Act target action date of December 3, 2026, marking a key milestone in Exelixis’ pipeline as it awaits a decision that could expand treatment options for this high-need population.
Navigating law and policy
Preparing for potential FDA approval brings unique legal responsibilities, including regulatory review, promotional planning, sales training, safety reporting and compliance oversight. At the same time, Brenda’ s team monitors health policy changes that directly affect biotech companies, such as drug pricing reforms and FDA regulatory updates.“ I was recently in Washington, DC, meeting with policymakers about FDA changes, drug pricing and other issues that affect us,” she adds.
Those policy debates create intense pressure for biotechnology companies whose revenue depends on a limited number of
products. Drug pricing programs, negotiation frameworks and reimbursement rules directly impact the resources companies have to reinvest in discovery and clinical development. For organizations built around a single commercial product, certain policy changes can have far-reaching consequences for long-term pipeline planning and investment decisions.
Litigation adds another dimension to the legal landscape. Since 2019, Exelixis has defended patents covering its commercial product under the Hatch- Waxman framework, which allows generic manufacturers to challenge an innovator company’ s patents after a set period following a drug’ s launch. In these cases, the company has protected its intellectual property and may negotiate agreements governing when generics may enter the market, balancing the need to maintain exclusivity with the realities of eventual competition. The experience has reshaped Brenda’ s patent strategy.“ You learn
americanhealthcareleader. com 53